Multimodal therapy for synergic inhibition of tumour cell invasion and tumour ...
11.03.10
Squamous cell carcinoma of the head and neck (SCCHN) are highly invasive tumours with frequent local and distant recurrence. Metastasis formation requires degradation of the extracellular matrix, which is fulfilled by membrane-associated proteases such as the urokinase plasminogen activator (uPA).
WX-UK1 is a competitive active site inhibitor of the protease function of uPA that impairs on the capacity of tumour cells to invade in vitro.
Methods: In the present study, effects of combinations of WX-UK1 with matrix metalloprotease inhibitors (MMP, galardin (R)) and cyclooxygenase-2 (COX-2, celecoxib(R)) inhibitors on tumour cell proliferation, invasion, and angiogenesis induction were evaluated. Matrigel invasion chambers and a spheroid co-cultivation model with human fibroblast served to determine the invasive potential of both FaDu (SCCHN) and HeLa (cervical carcinoma) cells, each treated with combinations of Celecoxib(R), Galardin(R), and WX-UK1.
Results: Blocking
Source: 7thSpace Interactive (press release)
NSAIDs Do Not Appear to Alleviate Depressive Symptoms in Older Adults ...
09.03.10
DGDispatch 
NSAIDs Do Not Appear to Alleviate Depressive Symptoms in Older Adults: Presented at AAGP By Carole VanSickle Ellis
SAVANNAH, Ga -- March 9, 2010 -- While several different lines of evidence seem to indicate that inflammatory mechanisms may be involved in the severity and progression of depression, the use of celecoxib and naproxen do not appear alleviate depressive symptoms in older adults.
The results were presented here on March 7 at the 2010 Annual Meeting of the American Association for Geriatric Psychiatry (AAGP) by Cynthia D. Fields, MD, Johns Hopkins Medicine, Baltimore, Maryland.
The team had speculated that using nonsteroidal anti-inflammatory drugs (NSAIDs) to relieve inflammation in the body could actually avert or slow the progress of depression.
For the study, researchers analysed date from patients in the randomised, placebo-controlled,
Source: DG News
Some painkillers have more bleeding risk than others
05.03.10
By Anne Harding
When it comes to gastrointestinal side effects, particularly bleeding into the stomach, not all painkillers known as non-steroidal anti-inflammatory drugs (NSAIDs) are created equal, new research shows.
“Balancing the safest NSAID with the most effective is always a trade off,” Dr. Luis A. Garcia Rodriguez of the Spanish Center for Pharmacoepidemiological Research in Madrid, one of the study’s authors, told Reuters Health via email.
For that reason, he added, people who need to use these drugs should choose those with the lowest gastrointestinal risks and use them for the shortest possible time at the lowest effective daily dose.
Stomach bleeding is a well-known risk factor of all NSAIDs, Garcia Rodriguez and his colleagues note in the journal Arthritis and Rheumatism. But the comparable risks of individual NSAIDs (such as ibuprofen), as well as those of newer NSAIDs called COX-2 inhibitors (like celecoxib, sold as Celebrex) are “still debated,” they add.
Source: Ethiopian Review
Another 18 volunteers received a five-day course of twice-daily 200 mg celecoxib and were randomized to the rosuvastatin or control groups on day four.
The use of non-steroidal anti-inflammatory drugs such as aspirin, ibuprofen and celecoxib offer no protection against a common skin cancer, according to a